A recent survey found encouraging results for the reduction in the use of mesalazine (anti-inflammatory) drug which is used to try and maintain colitis in remission mode.
Results from the largest prospective controlled ulcerative colitis (UC) trial conducted to date, called the QD dosing investigation for efficacy IN UC maintenance (QDIEM), found that once-daily dosing of Asacol(R) (mesalamine) delayed-release 400 mg tablets at 1.6-2.4 g/day was comparable to twice-daily dosing for the maintenance of remission in patients with UC. The study, which met its primary endpoint of non-inferiority, found that 90.5 per cent of patients taking Asacol once-daily remained in remission at six months compared to 91.8 per cent of patients taking Asacol twice-daily. These findings were announced at the American College of Gastroenterology (ACG) Annual Scientific Meeting in San Diego, California.
As always, consult you doctor if you wish to vary your medication.
A recent survey found encouraging results for the reduction in the use of mesalazine (anti-inflammatory) drug which is used to try and maintain colitis in remission mode.
Results from the largest prospective controlled ulcerative colitis (UC) trial conducted to date, called the QD dosing investigation for efficacy IN UC maintenance (QDIEM), found that once-daily dosing of Asacol(R) (mesalamine) delayed-release 400 mg tablets at 1.6-2.4 g/day was comparable to twice-daily dosing for the maintenance of remission in patients with UC. The study, which met its primary endpoint of non-inferiority, found that 90.5 per cent of patients taking Asacol once-daily remained in remission at six months compared to 91.8 per cent of patients taking Asacol twice-daily. These findings were announced at the American College of Gastroenterology (ACG) Annual Scientific Meeting in San Diego, California.
As always, consult you doctor if you wish to vary your medication.